Setting a Course for the Optimal Management of IBD
An Interactive Learning Experience
ACG Clinical Guidelines: Management of Crohn's Disease in Adults.
Lichtenstein GR, et al. Am J Gastroenterol. 2018;113(4):481-517.
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment.
Torres J, et al. J Crohns Colitis. 2020;14(1):4-22.
ACG Clinical Guideline: Ulcerative Colitis in Adults.
Rubin DT, et al. Am J Gastroenterol. 2019;114(3):384-413.
AGA Clinical Practice Guideline on the Management of Moderate to Severe Ulcerative Colitis.
Feuerstein JD, et al. Gastroenterology. 2020;158(5):1450-1461.
ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease.
Farraye F, et al. Am J Gastroenterol. 2017;112(2):241-258.
Suggested Readings
Mechanism-based treatment strategies for IBD: cytokines, cell adhesion molecules, JAK inhibitors, gut flora, and more.
Schreiner P, et al. Inflamm Intest Dis. 2019;4(3):79-96.
From bench to bedside: fecal calprotectin in inflammatory bowel diseases clinical setting.
Mumolo MG, et al. World J Gastroenterol. 2018;24(33):3681-3694.
The role of laboratory tests in Crohn’s disease.
Cappello M, Morreale GC. Clin Med Insights Gastroenterol. 2016;9:51-62.
A treat-to-target update in ulcerative colitis: a systematic review.
Ungaro R, et al. Am J Gastroenterol. 2019;114(6):874-883.
Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.
Coskun M, et al. Pharmacol Res. 2013;76:1-8.
JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?
Danese S, et al. Gut. 2019;68(10):1893-1899.
Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis.
Olivera PA, et al. Gastroenterology. 2020;158(6):1554-1573.
Tofacitinib as induction and maintenance therapy for ulcerative colitis.
Sandborn WJ, et al. N Engl J Med. 2017;377(5):496-497.
SELECTION: filgotinib for ulcerative colitis.
Brierley R. Lancet Gastroenterol Hepatol. 2020;5(12):1036-1037.
Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.
Vermeire S, et al. Lancet. 2017;389(10066):266-275.
Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn's disease.
Sandborn WJ, et al. Gastroenterology. 2020;158(8):2123-2138.
Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis.
Sandborn WJ, et al. Gastroenterology. 2020;158(8):2139-2149.
Patient Resources
American College of Gastroenterology
American Gastroenterological Association
Crohn’s and Colitis Foundation
European Crohn’s and Colitis Organisation
National Institute of Diabetes and Digestive and Kidney Diseases
Health Information for Crohn’s Disease
Health Information for Ulcerative Colitis
Relevant Resources
Advances in the Diagnosis and Treatment of Nonalcoholic Steatohepatitis
Got it? Treat it!
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
The Emerging Role of the Diabetologist
Key Issues Impacting OB/GYN Practice
An Interactive Experience Highlighting Recent Clinical Advances
Hot Topics in HBV, HCV, and NASH
Emerging Concepts in Patient Management
Building Your Understanding to Combat a Growing Problem
Why It Matters in OB/GYN Practice Today
How the Pharmacist Can Make a Difference
HIV Can Be Prevented— Are You Doing Your Part?
Rapid Start ART — A New Model for HIV Care
Understanding the Growing Syndemic — Opioids, HCV, and HIV
Appraising the Therapeutic Armamentarium in Moderate and Severe Disease
The PCP’s Role in HCV Elimination
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
